Business
Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors
New data supports the future development of LP-100 in combination with PARP inhibitors for earlier lines of treatment including metastatic prostate cancer
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nNew data supports the future development of LP-100 in combination with PARP inhibitors for earlier lines of treatment including metastatic prostate cancer and other indications where PARP inhibitors are being utilized.\n\n\nSynergistic potency was observed for LP-100 in combination with multiple PARP inhibitors and supported with in-silico analysis from billions of data points and real world patient data sets from RADR® - Lantern’s AI platform for drug development.\n\n\nLantern is exploring development of a new clinical trial in cancers with mutations in DDR (DNA Damage Response) genes such as BRCA1/2 and ATM, which will build upon the results from LP-100’s prior Phase 2 trial conducted in Denmark in metastatic castration-resistant prostate cancer (mCRPC).\n\n\nIn the Phase 2 clinical trial in Denmark, the median overall survival (OS) for the initial group of 9 patients was approximately 12.5 months, which is an improvement over other similar fourth-line treatment regimens for mCRPC.\n\n\nLantern estimates that the future development of LP-100 in combination with PARP inhibitors may increase the annual potential market size of LP-100 targeted indications to between $700 million and $2 billion, while also positioning the drug candidate in multiple genomically defined DDR cancers that align with its mechanism of action.\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"AI\") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced new data for its product candidate LP-100 supporting the development of LP-100 in combination with the class of anticancer agents known as PARP inhibitors (PARPi).\n\nIn prostate cancer mouse xenograft studies, LP-100 demonstrated synergistic potency when used in combination with the FDA-approved PARP inhibitor Olaparib. LP-100 also demonstrated synergy with the FDA-approved PARP inhibitors Olaparib, Rucaparib, and Niraparib in ovarian cancer cell line studies. The observations from these studies are further supported by in-silico evaluation of LP-100 in combination with PARP inhibitors using Lantern’s AI platform, RADR®.\n\n“The combined anti-tumor potency of LP-100 in combination with PARP inhibitors, s...